Prevention of oropharyngeal cancer due to human papillomavirus

Prevention of oropharyngeal cancer due to human papillomavirus refers to prophylactic clinical strategies aimed at averting malignant squamous cell neoplasms of the oropharynx—predominantly the tonsils and base of the tongue—caused by persistent infection with high-risk human papillomavirus subtypes, most notably HPV-16 Pathophysiologically, sustained high-risk HPV infection drives oncogenesis through the viral oncoproteins E6 and E7, which target and degrade the host tumor suppressors p53 and r...

Prevention of oropharyngeal cancer due to human papillomavirus refers to prophylactic clinical strategies aimed at averting malignant squamous cell neoplasms of the oropharynx—predominantly the tonsils and base of the tongue—caused by persistent infection with high-risk human papillomavirus subtypes, most notably HPV-16 This prophylactic indication applies broadly to eligible individuals prior to viral exposure, typically encompassing children, adolescents, and adults across genders Pathophysiol...

This prophylactic indication applies broadly to eligible individuals prior to viral exposure, typically encompassing children, adolescents, and adults across genders Prevention is primarily achieved through prophylactic immunization that induces neutralizing antibodies to block initial mucosal infection and subsequent persistent viral integration